Elevating the Prestige of K-Beauty with Innovative Technology Needle-Free Injection Device, Mirajet

The beauty medical device market accounts for 14% of Korea's total medical device market and has rapidly grown, surpassing 100 billion won in 2020. Amidst this explosive growth, so significant that it's dubbed the 'New growth Industry,' JSK Biomed, located in the Daedeok Innopolis in Daejeon, launched the needle-free injection device Mirajet in 2020, drawing significant attention in the skin beauty industry.
Unlike traditional air pressure injection methods, Mirajet employs a laser-generated high-energy dispersion technique to permeate the skin with medication. This technique offers precise energy control according to the patient's skin condition and enables up to 40 micro-jets per second without needle use. This results in minimal skin damage, making it highly effective for skin boosters and scar treatments.
In this April issue, we will explore JSK Biomed's growth, the domestic and international market response to Mirajet, and their future plans.

Q1. We introduced JSK Biomed in our newsletter back in 2020. How has the market responded to Mirajet since then?

As of March 2024, approximately 150 clinics in Korea have adopted Mirajet. Since its commercialization in 2020, sales have steadily increased with an annual growth rate of 50%. From the initial sale of 8 units in the first year, we have sold about 150 units in four years. This achievement is valuable to us, and we would like to express our sincere gratitude once again to the officials at the Daejeon Tourism Organization for their continued interest in our product and their support in promoting it.

Q2. How is Mirajet being utilized in Korean medical institutions?

Mirajet was developed to precisely deliver liquid medications to the necessary skin layer without a needle. Utilizing these features, skin rejuvenation treatments through 'low energy, high repetition' skin boosters are currently popular in Korea, along with treatments for scars, pores, and stretch marks. Recently, we have been researching the potential for hyperhidrosis and hair loss treatments through various tests with our key doctors and are establishing treatment protocols.

Q3. Are there ongoing research efforts to expand its application beyond skin beauty to general medical fields, such as vaccinations and insulin self-administration?

Our core technology leverages the explosive power of lasers to transform medication into a jet form that penetrates the skin without needles. Theoretically, based on the internal data, there is significant potential for application in general medical fields. However, our current focus is on delivering the medication as quickly, uniformly, and accurately as possible to the intended layer of the skin. Our research laboratory is dedicated to perfecting this technology. Our long-term plan includes the full-scale development of applications in general medical fields.

Q4. Clinical research results of 'Mirajet' were presented at the American Society for Laser Medicine and Surgery (ASLMS 2023) this spring. (What was the reaction from the medical community in the United States?)

In the spring of 2023, we had the opportunity to present our valuable clinical cases, achieved through many trials and errors, at ASLMS 2023. The research team, including seven dermatology specialists from Korea and abroad, such as Professor Heo Chang-hoon from Bundang Seoul National University Hospital, who has dramatically assisted since the development of Mirajet, participated in the academic study. The presentation was given by Dr. Seo Seokbae, a key doctor from SAS Dermatologic Clinic in Jamsil, introducing clinical cases where Mirajet's micro-injections into the skin layers showed remarkable effects on skin regeneration, lifting, anti-aging, and stretch mark treatments, attracting significant attention from the audience. Notably, after the presentation, Dr. Merete Haedersdal from Denmark, a world-renowned authority in drug delivery technology, expressed her interest in conducting further academic research in collaboration with JSK Biomed, stating, “This is an amazing technology that uses lasers to deliver small amounts of drugs to the skin, and it could completely change the drug delivery paradigm in medicine.” Additionally, Dr. Jane Yu from the United States mentioned, “Mirajet's ability to deliver various drugs to the skin without restrictions promises extensive applicability from facial skin rejuvenation to hair loss treatment and cellulite improvement across the body, raising high expectations for its application in the American market.” Dr. Yu introduced Mirajet in the United States and is actively working as a key doctor.

Q5. In 2020, Mirajet acquired the European Medical Device Certification (CE-MDD), which is issued only to products that meet the European Union's criteria for quality, performance, durability, and safety. This opens opportunities for market entry into the European Union and CE-recognizing countries. Is it being exported overseas as well?

As of the second quarter of 2023, we have officially entered the global market phase. Last year, we signed an exclusive distribution agreement with a Japanese agency, completing the first overseas export contract for about eight units of Mirajet, some of which have already been delivered to hospitals. Mirajet's procedures, characterized by minimal downtime and substantially fewer side effects, align with the preferences of Japanese consumers who favor treatments with almost no visible signs. Recently, Mirajet has been formally introduced at several dermatology and beauty conferences in Japan, and we anticipate a significant demand in the Japanese market within the next 1-2 years, potentially starting this year. Apart from Japan, we are smoothly progressing with business procedures in the European Union, the United Kingdom, China, Taiwan, and five key Southeast Asian countries, expecting Mirajet to be available to consumers in various countries in the near future.

Q6. 'Mirajet' is recognized as an innovative technology that elevates the quality of K-medical services. What are JSK Biomed's future plans?

Mirajet is acclaimed as an innovative technology that enhances the quality of K-medical services. As for the future plans of JSK Biomed, Mirajet is an innovative product of pure domestic technology, successfully mass-produced for the first time in Daejeon, South Korea. As a part of JSK Biomed, we have a mission to promote this excellent product, which carries the nationality of South Korea beyond Daejeon to the world, aspiring to make “Mirajet” synonymous with the Korean Wave (Hallyu) alongside “BTS, Bong Joon-ho, Son Heung-min.” Finally, with Mirajet as the starting point, JSK Biomed plans to expand its application fields beyond cosmetic purposes to include vaccines, insulin administration, local delivery of chemotherapeutics, aesthetics, and home care markets, aiming for a full-fledged entry into the medical market for disease prevention and treatment, based on our core patented technologies. Furthermore, as a global corporation, we are preparing to establish the next-generation Transdermal Drug Delivery System (TDDS) standards through continuous research and development based on our enhanced technological capabilities.

Source : JSK Biomed

Other Article